Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivaroxaban - Austhera Biosciences

Drug Profile

Rivaroxaban - Austhera Biosciences

Alternative Names: AST-8294; DST-8294; KRIVA

Latest Information Update: 08 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DisperSol Technologies
  • Class Amides; Anticoagulants; Antithrombotics; Cardiovascular therapies; Chlorinated hydrocarbons; Ketones; Morpholines; Oxazolidinones; Small molecules; Thiophenes
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Antiphospholipid syndrome

Most Recent Events

  • 05 Oct 2021 Biomarkers information updated
  • 10 Mar 2021 Rivaroxaban licensed to Austhera Biosciences prior to March 2021 (Austhera Biosciences pipeline, March 2021)
  • 25 Sep 2020 DisperSol Technologies has patent protection for KinetiSol® technology before September 2020 (DisperSol Technologies website, September 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top